Dec. 30, 2013 – In the wake of the GlaxoSmithKline (GSK) decision to stop paying physicians for speaking engagements and attendance at medical conferences, a debate has been sparked over the value of these activities, according to two recent articles in Policy and Medicine.

In a Dec. 17 article, Policy and Medicine wrote about GSK’s announcement that it would end payments to physicians who speak on their behalf, and on Dec. 19, the publication covered a PBS interview of Dr. Jerry Avorn and Dr. Thomas Stossel, both of Harvard Medical School, “about the business and ethical issues surrounding GSK’s decision and whether doctors should be paid by pharmaceutical companies to promote their drugs.”To read the Dec. 19 Policy and Medicine article, go to: http://www.policymed.com/2013/12/pbs-debate-should-doctors-be-paid-by-pharmaceutical-companies-to-promote-their-drugs.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+policymed+%28Policy+and+Medicine%29